NEOS Investment Management LLC Grows Stock Position in Solventum Co. (NYSE:SOLV)

NEOS Investment Management LLC increased its holdings in Solventum Co. (NYSE:SOLV) by 24.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,359 shares of the company’s stock after acquiring an additional 1,236 shares during the period. NEOS Investment Management LLC’s holdings in Solventum were worth $420,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SOLV. New York Life Investment Management LLC raised its stake in shares of Solventum by 0.7% in the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock valued at $1,223,000 after acquiring an additional 136 shares during the period. Blue Trust Inc. increased its holdings in Solventum by 2.1% in the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after purchasing an additional 161 shares during the last quarter. MML Investors Services LLC raised its position in Solventum by 3.2% in the third quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after purchasing an additional 168 shares during the period. Avantax Advisory Services Inc. lifted its stake in Solventum by 2.2% during the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after purchasing an additional 192 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Solventum by 48.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company’s stock worth $45,000 after buying an additional 223 shares during the period.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several research reports. Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Piper Sandler increased their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Mizuho lifted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. The Goldman Sachs Group increased their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Finally, Morgan Stanley upped their price objective on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Solventum currently has an average rating of “Hold” and an average target price of $79.86.

Solventum Price Performance

Shares of SOLV opened at $76.02 on Tuesday. The firm has a market capitalization of $13.15 billion and a price-to-earnings ratio of 27.64. The firm’s fifty day simple moving average is $75.56 and its 200-day simple moving average is $71.92. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.